oncgnostics GmbH

Company Profile Reliably detecting cancer using epigenetic biomarkers oncgnostics develops and markets - based on proprietary epigenetic biomarkers - highly reliable, molecular biology-based in vitro diagnostic (=IVD) tests for screening, therapeutic decisions and follow-up care in cancer diagnostics. First product will be GynTect, an IVD for detecting cervical (pre-) cancer cases. Pipeline projects are in the field of head and neck cancer and ovarian cancer diagnostics.